title: Age-response effectiveness of gallopamil for the treatment of myocardial exertional ischemia. A medium-term randomized cross-over double-blind placebo-controlled trial.
abstract: We evaluated the efficacy and safety of gallopamil 150 mg daily in middle-aged and elderly patients with stable exertional ischemia, using a medium-term randomized double-blind cross-over placebo-controlled trial. Twenty middle-aged patients (52.8 +/- 6 years; range 38-61 years) and 14 elderly patients (67.4 +/- 2.8 years; range 65-73 years) with stable exertional ischemia underwent a bicycle exercise test. After a run-in period, both groups received treatment with either placebo or gallopamil 50 mg tid for 28 days. At the end of this time, each patient crossed over to the alternate regimen. Gallopamil significantly reduced heart rate, blood pressure and rate pressure product (from 15.37 +/- 2.7 to 13.65 +/- 4.16 U x 10(-3); p < 0.01) in elderly patients at submaximal exercise, but had no effect in middle-aged patients (from 14.52 +/- 4.45 to 13.49 +/- 3.77 U x 10(-3); p = NS). At peak exercise, none of the hemodynamic parameters was modified with gallopamil in either group. At peak exercise, both middle-aged and elderly patients achieved rate-pressure products similar to those reached during placebo at higher work loads. Exercise duration and maximal work load significantly increased in both groups. Electrocardiographic signs of ischemia were favorably influenced by gallopamil in both groups (from 1.39 +/- 0.5 mm to 0.76 +/- 0.73 mm; p < 0.001 in the middle-aged patients and from 1.5 +/- 0.34 mm to 1 +/- 0.76 mm; p < 0.01 in the elderly patients).(ABSTRACT TRUNCATED AT 250 WORDS)
authors.affiliation: Fondazione Clinica del Lavoro, Centro Medico di Campoli, Istituto di Ricovero e Cura a Carattere, Scientifico, Campoli del Monte Taburno, Benevento, Italy.
authors.forename: D
authors.initials: D
authors.lastname: Acanfora
authors.forename: L
authors.initials: L
authors.lastname: Odierna
authors.forename: L
authors.initials: L
authors.lastname: De Caprio
authors.forename: G
authors.initials: G
authors.lastname: Longobardi
authors.forename: C
authors.initials: C
authors.lastname: Rengo
authors.forename: N
authors.initials: N
authors.lastname: Guerra
authors.forename: G
authors.initials: G
authors.lastname: Furgi
authors.forename: O F
authors.initials: OF
authors.lastname: Bollella
authors.forename: C
authors.initials: C
authors.lastname: Picone
authors.forename: F
authors.initials: F
authors.lastname: Rengo
mesh_terms: D000328:Adult; D017677:Age Distribution; D000368:Aged; D000792:Angiography; D003326:Coronary Circulation / Q000187:drug effects; D018592:Cross-Over Studies; D004311:Double-Blind Method; D005080:Exercise Test; D005260:Female; D005711:Gallopamil / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D017202:Myocardial Ischemia / Q000188:drug therapy*; D005082:Physical Exertion; D010919:Placebos; D015203:Reproducibility of Results; D016037:Single-Blind Method; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D010919:Placebos; D014665:Vasodilator Agents; D005711:Gallopamil